Top Bristol-Myers shareholder does not support $74 billion Celgene deal

Bristol-Myers Squibb Co's top shareholder Wellington Management said on Wednesday that it did not support the U.S. drugmaker's $74 billion purchase of biotech Celgene Corp , saying the deal is too risky.